Released in the New England Journal of Medication.

Amgen announces romosozumab Phase 2 trial outcomes in postmenopausal females with low BMD Amgen and UCB today announced outcomes from a Phase 2 trial evaluating romosozumab in postmenopausal females with low bone mineral density 3-4 months . Released in the New England Journal of Medication , the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months considerably increased BMD at the lumbar spine, total hip and femoral throat.

Other Posts From "gear":

Related Posts